8 October 2024 UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license agreement for AVB-101.
Months after estimating that a fair US price for Pfizer’s Paxlovid (nirmatrelvir/ritonavir) would be between $3,600 and $5,800, the Institute for Clinical and Economic Review (ICER) has drastically changed its view. 21 December 2022
Respiratory disease specialist Verona Pharma has seen its shares jump from around $13 to $18 following positive results from the Phase III ENHANCE-1 trial. 21 December 2022
US clinical-stage biotech Magenta Therapeutics has halted dosing in one of the groups taking part in a Phase I/II study of cancer candidate MGTA-117. 21 December 2022
UK pharma major AstraZeneca today announced two approvals from the European Commission for expanded indications for its blockbuster cancer drugs, one for Imfinzi (durvalumab) and the other for Lynparza (olaparib). 21 December 2022
The volume of drug production in Russia is steadily growing this year despite the ever-tightening sanctions regime and international isolation of Russia, according to recent statements by some leading local pharma analysts and the Russian media, reports The Parma Letter’s local correspondent. 21 December 2022
Danish allergy immunotherapy specialist ALK Abello today announced that Dr Henriette Mersebach will join the company as executive vice president, research and development and member of the board of management. 21 December 2022
The European Commission (EC) has granted conditional marketing authorization for the use of Zynlonta (loncastuximab tesirine) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), Swedish Orphan Biovitrum, also known as Sobi, and Switzerland’s ADC Therapeutics announced today. 21 December 2022
Russian patients with Parkinson's disease have faced a shortage of life-saving drugs based on levodopa, as, according to latest data of the Russian analyst agency RNC Pharma, the supply of these drugs has decreased by 49% in a year. 21 December 2022
Life sciences industry analyst GlobalData has identified significant opportunities for drug developers in the area of diabetic neuropathic pain medicine. 20 December 2022
US biotech major Gilead Science today revealed that its Kite subsidiary has reached agreement to acquire privately-held Tmunity Therapeutics, a start-up set up by Carl June and his colleagues at the University of Pennsylvania and with former Novartis heavyweight Usman ‘Oz’ Azam as chief executive. 20 December 2022
Japanese drugmaker Eisai saw its shares fall nearly 4% to 9,038 yen today, after it announced it is divesting US rights to its anti-epileptic drug Fycompa (perampanel) to Catalyst Pharmaceuticals, whose shares moved up 7.4% to $17.63 on the news. 20 December 2022
The US Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Applications (sBLAs) for Seagen and Astellas’ Padcev (enfortumab vedotin-ejfv) and Merck & Co’s Keytruda (pembrolizumab). 20 December 2022
Californian companies Gilead Sciences and Arcus Biosciences have announced positive results from the fourth interim analysis of the ARC-7 study. 20 December 2022
German pharma major Boehringer Ingelheim and US tech-based therapy firm Click Therapeutics have announced the launch of an expanded collaboration on a second prescription-based digital therapeutic (PDT). 20 December 2022
Japan’s Daiichi Sankyo today announced it has launched Ezharmia (valemetostat tosilate), a first-in-class dual inhibitor of EZH1 and EZH2, in Japan for the treatment of patients with relapsed or refractory adult T-cell leukemia-lymphoma (ATLL). 20 December 2022
When in April this year US pharma giant Pfizer acquired ReViral for $525 million, along with its portfolio of respiratory syncytial virus (RSV) therapeutic candidates, it did not include development and commercialization rights for ReViral lead candidate sisunatovir in China and certain other Asian markets, which China’s LianBio had already in-licensed in March 2021. 20 December 2022
Ireland-based cancer focused biopharma Carrick Therapeutics and family-owned Italian pharma Menarini have announced a clinical trial collaboration and supply agreement. 20 December 2022
Switzerland-based Idorsia today announced that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) seeking approval for aprocitentan, the firm’s investigational, novel dual endothelin receptor antagonist, for the treatment of patients with difficult-to-control hypertension. 20 December 2022
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
Sage Therapeutics’ share price fell 11% to $6 in pre-market activity on Tuesday, after it announced disappointing top-line results from LIGHTWAVE. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Bayer has entered into a collaboration with MOMA Therapeutics to develop a small molecule oncology program using the latter’s proprietary KNOMATIC platform. 9 October 2024
The UK has launched a new Regulatory Innovation Office (RIO), with the goal of accelerating new technologies, particularly in sectors like biotech and healthcare, by reducing regulatory barriers. 9 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Some two-and-a-half years after buying the Novo Holdings portfolio company ReViral and its respiratory syncytial virus (RSV) candidate sisunatovir in a deal worth up to $525 million, US pharma giant Pfizer may have signalled an early end to the pricey project. 9 October 2024
US pharma major Bristol Myers Squibb’s recent approval from the US Food and Drug Administration (FDA) for Cobenfy (xanomeline and trospium chloride) for the treatment of adults with schizophrenia is a win for the company. 9 October 2024
Cambridge, USA-based City Therapeutics has announced its launch with a vision to lead the future of RNA interference (RNAi)-based medicine. 9 October 2024
Zephyrm Bioscience, a Cayman Islands-based biotech, has filed for an initial public offering (IPO) in Hong Kong, seeking to raise additional capital to advance its cell therapy pipeline. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024
Genor Biopharma has announced plans for a significant merger with Edding Group, marking one of the first reverse takeovers involving a Hong Kong-listed biopharma company. 8 October 2024
UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license agreement for AVB-101. 8 October 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
A clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.